Diagnosis and management of juvenile idiopathic arthritis

FHM Prince, MH Otten, LWA van Suijlekom-Smit - Bmj, 2010 - bmj.com
Diagnosis and management of juvenile idiopathic arthritis | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons

MH Otten, J Anink, S Spronk… - Annals of the rheumatic …, 2013 - ard.bmj.com
Objective Over the past decade, the availability of biological agents for the treatment of
juvenile idiopathic arthritis (JIA) has increased substantially. Because direct head-to-head …

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

D Holzinger, M Frosch, A Kastrup… - Annals of the …, 2012 - ard.bmj.com
Background Analysis of myeloid-related protein 8 and 14 complex (MRP8/14) serum
concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile …

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

MH Otten, FHM Prince, W Armbrust, R ten Cate… - Jama, 2011 - jamanetwork.com
Context Since the introduction of biologic therapies, the pharmacological treatment
approach for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement …

[HTML][HTML] MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis

J Anink, LWA Van Suijlekom-Smit, MH Otten… - Arthritis Research & …, 2015 - Springer
Introduction Approximately 30% of juvenile idiopathic arthritis (JIA) patients fail to respond to
anti-TNF treatment. When clinical remission is induced, some patients relapse after …

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

MH Otten, J Anink, FHM Prince, M Twilt… - Annals of the …, 2015 - ard.bmj.com
Background Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since
the introduction of biological agents in 1999. Objective To evaluate trends in prescription …

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register

MH Otten, FHM Prince, J Anink, R Ten Cate… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the effectiveness and safety of switching to a second or third
biological agent in juvenile idiopathic arthritis (JIA) after etanercept failure. Methods The …

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biologicals in children register, 1999–2010

MH Otten, FHM Prince, M Twilt, W ARMBRUST… - The Journal of …, 2011 - jrheum.org
Objective. To evaluate the effectiveness and safety of biological agents in children with
enthesitis-related arthritis (ERA). Methods. All patients with ERA in whom a biological agent …

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and …

J Anink, FHM Prince, M Dijkstra, MH Otten… - …, 2015 - academic.oup.com
Objective. To carry out a longitudinal investigation of functional outcome, health-related
quality of life (HRQoL) and treatment strategies in JIA patients who started etanercept> 5 …

Neurocognitive, psychosocial, and quality of life outcomes after multisystem inflammatory syndrome in children admitted to the PICU

MH Otten, CMP Buysse, EP Buddingh… - Pediatric critical care …, 2023 - journals.lww.com
OBJECTIVES: To investigate neurocognitive, psychosocial, and quality of life (QoL)
outcomes in children with Multisystem Inflammatory Syndrome in Children (MIS-C) seen 3–6 …